Table 1 Baseline characteristics and Jadad score of included study
Authors publish time | Study phase | Location | Sample characteristics | Trial quality | |||||
|---|---|---|---|---|---|---|---|---|---|
Age (years) | Sex: male | Race | Blinding described, appropriate | Randomization described, appropriate | Losses to follow-up described | Jadad score | |||
Jan van Lunzen et al. 2012. [20] | Phase IIb | France, Germany, Italy, Russia, Spain, the USA | ≥18 DTG: 10 mg (Mean = 32) 25 mg( Mean = 38) 50 mg (Mean = 37) EFV: 600 mg (Mean = 40) | DTG: 10 mg (42/53) 25 mg (46/51) 50 mg (45/51) EFV: 600 mg (44/50) | White: (164/205, 80 %) Black: (25/205, 12 %) Other: (16/205, 8 %) | Yes, yes | Yes, yes | Yes | 5 |
S. Walmsley et al. 2012. [22] | Phase III | Toronto, Canada, Belgium, Spain, Italy | DTG: 50 mg (Mean = 36) EFV: 50 mg (Mean = 35) | DTG: 50 mg (378/414) EFV: 400 mg (63/419) | White: (566/833, 68 %) Black: (200/833, 24 %) Other: (67/833, 6 %) | Yes, yes | Yes, yes | Yes | 5 |
Pedro Cahn et al. 2013. [23] | Phase III | (156 centers) Australia, Canada, Europe, Latin, America, Taiwan, South Africa, the USA | ≥18 DTG: 50 mg (Mean = 42) RAL: 400 mg (Mean = 43) | DTG: 50 mg (247/354) RAL: 400 mg (238/361) | White: (347/715, 49 %) Black: (303/715, 42 %) Other: (65/715, 9 %) | Yes, yes | Yes, yes | Yes | 5 |
Francois Raffi et al. 2013. [21] | Phase III | (100 sites) Canada, USA, Australia, Europe | ≥18 DTG: 50 mg (Mean = 37) RAL: 400 mg (Mean = 35) | DTG: 50 mg (348/411) RAL: 400 mg (355/411) | White: (698/822, 85 %) Black: (88/822, 11 %) Other: (36/822, 4 %) | Yes, yes | Yes, yes | Yes | 5 |